An obscure Roche dataset reignites the Tigit space, and sends up Arcus, Compugen and Iteos.
Cellular Biomedicine Group has had a rollercoaster existence, and emerged from obscurity this week with a $245m injection from J&J.
No news is bad news for the Mariposa trial, J&J’s bid for market share in lung cancer, but Carvykti turns the frown upside down.
If at first you don’t succeed... Regeneron follows the underwhelming linvoseltamab with something it hopes will be better.
But, as Celyad bows out, how do you compete in a field as crowded as this?
The group highlighted Carvykti, nipocalimab and milvexian among its potential mega-blockbusters.